APOKYN is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Us Worldmeds, Llc. The primary component is Apomorphine Hydrochloride.
Product ID | 27505-004_2e6d5ae5-b402-4b99-ae2e-9c629782f2d2 |
NDC | 27505-004 |
Product Type | Human Prescription Drug |
Proprietary Name | APOKYN |
Generic Name | Apomorphine Hydrochloride |
Dosage Form | Injection |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2004-07-02 |
Marketing Category | NDA / NDA |
Application Number | NDA021264 |
Labeler Name | US WorldMeds, LLC |
Substance Name | APOMORPHINE HYDROCHLORIDE |
Active Ingredient Strength | 30 mg/3mL |
Pharm Classes | Dopamine Agonists [MoA],Dopaminergic Agonist [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2004-07-02 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA021264 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2004-07-02 |
Marketing Category | NDA |
Application Number | NDA021264 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2004-07-02 |
Ingredient | Strength |
---|---|
APOMORPHINE HYDROCHLORIDE | 30 mg/3mL |
SPL SET ID: | 3235535d-9ef9-4657-8b2a-176a807d091c |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
27505-004 | APOKYN | APOMORPHINE HYDROCHLORIDE |
52817-720 | apomorphine hydrocloride | APOMORPHINE HYDROCHLORIDE |
10191-1225 | APOMORPHINUM MURIATICUM | APOMORPHINE HYDROCHLORIDE |
63402-010 | KYNMOBI | apomorphine hydrochloride |
63402-015 | KYNMOBI | apomorphine hydrochloride |
63402-020 | KYNMOBI | apomorphine hydrochloride |
63402-025 | KYNMOBI | apomorphine hydrochloride |
63402-030 | KYNMOBI | apomorphine hydrochloride |
63402-088 | KYNMOBI | apomorphine hydrochloride |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
APOKYN 78269572 2973482 Live/Registered |
BRITUSWIP LIMITED 2003-07-02 |